Marina Fest, NP
Family · Staten Island, NYNPI 1285020842
Payments from drug & device makers
Across 332 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$492
- GSK$433
- Intra-sana Laboratories$342
- Lilly USA, LLC$334
- AstraZeneca$289
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,44899%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $2,464 |
| Pfizer | 27 | $492 |
| GSK | 19 | $433 |
| Intra-sana Laboratories | 8 | $342 |
| Lilly USA, LLC | 16 | $334 |
| AstraZeneca | 16 | $289 |
| Antares Pharma, Inc. | 9 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $268 |
| Scilex Pharmaceuticals Inc. | 13 | $250 |
| Astellas Pharma US Inc | 9 | $229 |
| Ardelyx, Inc. | 10 | $222 |
| Kowa Pharmaceuticals America, Inc. | 12 | $146 |
| Axsome Therapeutics, Inc. | 5 | $139 |
| Almatica Pharma LLC | 5 | $95 |
| Corcept Therapeutics | 3 | $70 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Scynexis, Inc. | 2 | $41 |
| Organon | 2 | $41 |
| Exact Sciences | 2 | $37 |
| Novo Nordisk | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Amgen | 1 | $17 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$150
- GLYCATE$150
- Reltone 400 Mg$150
- NOCDURNA$125
- Creon$125
How this compares
$6,509 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 150 | $119,514 |
| MounjaroTirzepatide | 51 | $54,579 |
| Baclofen | 21 | $52,208 |
| Metformin Hcl | 130 | $34,620 |
| CreonLipase/Protease/Amylase | 32 | $34,124 |
| EliquisApixaban | 34 | $27,128 |
| JanuviaSitagliptin Phosphate | 22 | $17,238 |
| RyventCarbinoxamine Maleate | 24 | $16,593 |
| UbrelvyUbrogepant | 13 | $16,090 |
| VascepaIcosapent Ethyl | 41 | $16,048 |
| ZenpepLipase/Protease/Amylase | 18 | $15,810 |
| XareltoRivaroxaban | 28 | $15,597 |
| XyostedTestosterone Enanthate | 21 | $15,337 |
| QuliptaAtogepant | 11 | $11,823 |
| TrulancePlecanatide | 21 | $11,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Ubrelvy, Qulipta, Linzess, Synthroid | $2,464 | $70,40492 claims |
| Lilly USA, LLCMounjaro | $334 | $54,57951 claims |
| PfizerEliquis | $492 | $27,12834 claims |
| Antares Pharma, Inc.Xyosted | $271 | $15,33721 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $268 | $11,12021 claims |
| GSKTrelegy Ellipta | $433 | $9,94816 claims |
| Astellas Pharma US IncMyrbetriq | $229 | $8,72519 claims |
| Scilex Pharmaceuticals Inc.Ztlido, Colchicine | $250 | $5,63153 claims |
| AstraZenecaBrilinta | $289 | $5,47413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Staten Island
- John de OcaStaten Island$86K
- Daniel OstrowskiStaten Island$25K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.